Z variant heterozygosity in alpha-1 antitrypsin deficiency: disease risk and treatment implications

By afschroeder • April 9, 2026

Hersh CP, Teckman JH, Strnad P, Hakim A, Carroll TP, Hall IP, Ghosh AJ, Barjaktarevic I, McElvaney NG, Kaserman JE, Lomas DA, Strange C, Drummond MB, Rennard S, Hanna KE, Clark VC, Goldklang MP, Iverson P, Wilson AA. Z variant heterozygosity in alpha-1 antitrypsin deficiency: disease risk and treatment implications. Orphanet J Rare Dis. 2026 Apr 8;21(1):136. doi: 10.1186/s13023-026-04283-9. PMID: 41952152.

Tags: alpha-1 antitrypsin, alpha-1 antitrypsin deficiency, Augmentation therapy, Carrier state, chronic liver disease, COPD, Heterozygote, Publications, Pulmonary, Critical Care & Sleep Medicine, rare disease

Patterns of Adherence and Persistence to Triple and Quadruple Guideline-Directed Medical Therapy Among US Patients With Heart Failure With Reduced Ejection Fraction

Fonarow GC, Coyle CR, Obi EN, Marks-Anglin AK, Alipour-Haris G, Stevenson AS. Patterns of Adherence and Persistence to Triple and Quadruple Guideline-Directed Medical Therapy Among[...]

Ethical Considerations in the Use of Indwelling Lines in Persons Who Use Injection Drugs

Green AS, Feldman WB, Solomon DA. Ethical Considerations in the Use of Indwelling Lines in Persons Who Use Injection Drugs. Clin Infect Dis. 2026 Apr[...]

Editorial Comment

Melamed S, Waterman B, Bergman J. Editorial Comment. Urol Pract. 2026 Apr 29:101097UPJ0000000000001018. doi: 10.1097/UPJ.0000000000001018. Epub ahead of print. PMID: 42047621.